Ginkgolide B composite medicine eluting stent

A ginkgolide and stent-eluting technology, which is applied in the fields of drug combination, medical science, blood diseases, etc., can solve the problem of unsolved delay in endothelialization, achieve good vascular endothelial cell growth, inhibit restenosis, and prevent stents. The effect of blood clots

Inactive Publication Date: 2015-06-17
SHANGHAI PUTUO DISTRICT CENT HOSPITAL
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some researchers have used arsenic as the carrier drug of drug-eluting stents, and confirmed that it has a good anti-restenosis effect, but its effect is similar to that of rapamycin drug-eluting stents currently on the market, and its endothelialization delay has not yet been resolved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ginkgolide B composite medicine eluting stent
  • Ginkgolide B composite medicine eluting stent
  • Ginkgolide B composite medicine eluting stent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Properties of ginkgolide B composite drug-eluting stent.

[0032] (1) Preparation of ginkgolide B composite drug-eluting stent.

[0033] After mixing liquid ginkgolide B, rapamycin and polylactic acid in an equal ratio of 1:1:1, the resulting slurry is coated on the surface of the stent by spraying or soaking. After the drug coating is prepared, the drug content is determined by weighing, and then the obtained stent is dried and stored at low temperature.

[0034] (2) Detection of coating adhesion of ginkgolide B composite drug-eluting stents.

[0035] Balloons were embedded on the surface of the stent, and the ginkgolide B composite drug-eluting stent was inflated at 12 atmospheres for 12 seconds, and then observed under a scanning electron microscope. The surface of the stent was uniform and smooth (see figure 1 a), under a 100x electronic scanning microscope (see figure 1 As shown in b), the surface coating of the stent has no obvious tearing, indicatin...

Embodiment 2

[0042] Example 2: Observing the effects of ginkgolide B-sirolimus composite drug-eluting stent on antithrombotic, promoting endothelialization and anti-restenosis.

[0043] (1) Arteriovenous shunt experiment.

[0044] Methods: The pigs in this experiment were all treated with aspirin and clopidogrel antithrombotic effect. Under sterile conditions, the porcine femoral artery and femoral vein were separated, and a sterilized 30 cm × 3 mm leather tube was used to connect the arteriovenous to form arteriovenous circulation. GB-RAP (ginkgolide B-rapamycin) stent, RAP (Rapamycin) stents and BMS (bare metal stents, traditional bare metal stents) were expanded in the leather tube. Three samples were repeated for each stent, and 3 miniature pigs were used for the experiment, and different For the 3 stents in the group, one stent was placed in each vessel, the blood was perfused, the blood flow was controlled at 90 ml / min, the perfusion was 60 min, the tubes were separated, the stents ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention discloses a ginkgolide B composite medicine eluting stent which is a stent of which the surface is covered with a medicine coating containing ginkgolide B, sirolimus and polylactic acid, wherein the ratio of ginkgolide B to sirolimus to polylactic acid is 1 to (0.6-1.4) to (0.5-1.5); and each 10mm stent respectively contains 8-12mcg of ginkgolide B and 7-10mcg of sirolimus. The composite medicine eluting stent is capable of promoting vascular endothelial cell growth, resisting thrombus and resisting vascular restenosis. The medicine coating is smooth and evenly covers the stent surface; the thickness of the medicine coating is 5-10 microns; the medicine slow-release time of the medicine coating is greater than or equal to 28 days; and the medicine release rate can reach 85%. The ginkgolide B composite medicine eluting stent disclosed by the invention has good effects of resisting thrombus, promoting endothelialization of intravascular stent and resisting vascular restenosis, and can be used as a choice of a new generation of coronary medicine stent.

Description

technical field [0001] The invention relates to a drug-eluting stent, in particular to a ginkgolide B composite drug-eluting stent. Background technique [0002] Drug-eluting stents can significantly reduce the incidence of restenosis in coronary intervention, but poor endothelialization of stents and late stent thrombosis are prominent problems in percutaneous coronary intervention. Recent studies have shown that complications such as stent thrombosis, polymer hypersensitivity, stent malapposition, and aneurysm may occur after drug-eluting stent implantation. ) is the most serious complication, which has attracted great attention of scholars at home and abroad. Studies have shown that the main drug-eluting stents in clinical use (such as rapamycin and paclitaxel-eluting stents) have delayed stent endothelialization after implantation in blood vessels, and may be the main cause of late stent thrombosis, thereby promoting injury Early repair of coronary endothelium, reducti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L31/10A61L31/16A61L31/14A61K31/436A61P7/02A61P9/14A61K31/365
Inventor 郜俊清刘宗军殷佩浩于文陈弢
Owner SHANGHAI PUTUO DISTRICT CENT HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap